Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is new capsule form. T-1101 capsule IND application has been approved by FDA in Nov, 2020 and further by TFDA in Dec, 2020.

T-1101:

T-1101 Phase I trial is the first-in-human study conducted to evaluate the safety and tolerability of T-1101 capsule in patients with solid tumors that were refractory to standard-of- care therapy. T-1101 capsules will be orally administered once or twice daily in a 28-day cycle for 2 cycles during the dose escalation phase.